Abstract
Clozapine is effective in managing patients with treatment‐resistant schizophrenia. Clinicians who use this drug are generally well aware of the need to monitor patients for infrequent but well‐recognized and potentially life‐threatening adverse effects, such as agranulocytosis. Clozapine also has more common adverse effects that are generally considered to entail less medical risk, such as sialorrhea (excessive salivation). Some reports suggest a risk of aspiration pneumonia related to clozapine‐induced sialorrhea.1,2,3 A clinical report recently described an occurrence of aspiration pneumonia as a result of clozapine exposure.4
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
